Document is current
Any future updates will be listed below
-
Authors
Melson, Eka https://orcid.org/0000-0003-0685-4819
Ashraf, Uzma
Papamargaritis, Dimitris https://orcid.org/0000-0001-5044-1515
Davies, Melanie J. https://orcid.org/0000-0002-9987-9371
- License Information
-
More Information
Article History
Received: 15 October 2023
Revised: 12 January 2024
Accepted: 15 January 2024
First Online: 1 February 2024
Competing interests
: E.M. and U.A. declare no competing interest. D.P. has acted as a speaker for Novo Nordisk and has received grants from Novo Nordisk, Novo Nordisk UK Research Foundation, Academy of Medical Sciences/ Diabetes UK and Health Education East Midlands. M.J.D. has acted as consultant, advisory board member and speaker for Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi, an advisory board member Lexicon, Pfizer, ShouTi Pharma Inc, AstraZeneca and Medtronic and as a speaker for AstraZeneca, Napp Pharmaceuticals, Novartis and Amgen. M.J.D has received grants from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janssen and Sanofi-Aventis and Eli Lilly.
